Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-00491 |
IL-18BP Protein, Cynomolgus, Recombinant (His)
Igifbp,Interleukin-18-binding protein<... |
Cynomolgus | HEK293 Cells |
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Cynomolgus, Recombinant (His) is expressed i... | |||
TMPK-00492 |
IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated
Igifbp,Interleukin-18-binding protein<... |
Cynomolgus | HEK293 Cells |
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombi... |